For decades, the fight against cancer has focused primarily on the genetic mutations that drive tumor growth or the physical removal of malignant masses. But, a paradigm shift is occurring in oncology. Researchers are increasingly focusing on the “engine” that powers these cells: their metabolism. By identifying the fundamental differences in how cancer cells consume energy compared to healthy cells, scientists are working to starve tumors and sensitize them to existing treatments.
This frontier of research, known as immuno-metabolism in cancer therapy, seeks to exploit the metabolic vulnerabilities of tumors. Because malignant cells must proliferate rapidly, they undergo “metabolic reprogramming,” altering their internal chemistry to sustain aggressive growth. This unique dependency creates a strategic opening—a point of weakness that can be targeted to stop the progression of the disease.
The transition from laboratory discovery to bedside application is often the most demanding phase of medical progress. Scientists refer to this as the “last mile” of research. Current initiatives in Europe and the United States are now aggressively pursuing this transition, combining specialized research funding, nutritional clinical trials, and the repurposing of metabolic drugs to improve patient survival rates.
The ‘Last Mile’: Targeting Metabolic Reprogramming in Solid Tumors
A significant step in bridging the gap between theory and therapy is the recently announced collaboration between the Algebris Ets foundation and the Istituto Airc di Oncologia molecolare (Ifom). This partnership has established a sponsored research program lasting two years, specifically dedicated to the study of oncology immuno-metabolism announced on April 7, 2026.
The program is led by Claudio Vernieri, a surgeon and researcher specializing in clinical oncology and tumor metabolism. Under Vernieri’s direction, the Ifom research program, titled “Metabolic Reprogramming in Solid Tumors,” focuses on the precise ways cancer cells alter their metabolism to survive and thrive. By understanding these pathways, the team aims to develop therapies that disrupt the tumor’s energy supply without harming the surrounding healthy tissue.
This approach is based on the premise that the metabolic needs of a tumor are distinct from those of a normal cell. Even as healthy cells maintain a balanced energy equilibrium, tumor cells are often “addicted” to specific nutrients to fuel their rapid division. Targeting these specific metabolic dependencies allows clinicians to strike the tumor where it is most vulnerable, potentially reducing the systemic toxicity often associated with traditional chemotherapy.
Integrating Nutrition as a Clinical Tool
Beyond pharmacological interventions, the intersection of nutrition and oncology is becoming a primary component of therapeutic strategies. The goal is no longer just to maintain a patient’s weight during treatment, but to use nutrition as a biological lever to enhance the efficacy of other therapies.
At the third edition of the Meet Immune Conference, held May 5-6, 2025, at the Istituto Nazionale dei Tumori in Milan, experts discussed the theme “How Metabolism Meets the Immune System in Human Malignancies” reported May 6, 2025. The conference highlighted a critical synergy: the metabolic state of the patient directly influences the behavior of the immune system, which in turn dictates how the body responds to cancer.
One of the most promising areas of this research is the use of caloric restriction and fasting-mimicking diets. Evidence suggests that these dietary interventions can strengthen the “biological terrain” in which antitumor therapies operate. Specifically, modulating the patient’s metabolism may improve the response to:
- Immunomodulating drugs: Enhancing the ability of the immune system to recognize and attack cancer cells.
- Radioligands: Improving the precision and impact of targeted radiation therapies.
This integrated approach is particularly vital for complex and aggressive malignancies. Experts are focusing these nutritional strategies on high-risk cases, such as triple-negative breast cancer and small-cell lung cancer, where traditional treatments often face resistance. By combining targeted nutrient selection with neoadiuvant therapies, clinicians hope to create a metabolic environment that is hostile to the tumor but supportive of the patient’s immune defense.
Repurposing Metabolic Drugs: The Impact of GLP-1 Agonists
While dietary changes offer a non-pharmacological route to metabolic control, the repurposing of existing metabolic medications is showing surprising results in oncology. Specifically, GLP-1 (glucagon-like peptide-1) receptor agonists—drugs widely known for treating obesity and type 2 diabetes, such as Ozempic, Wegovy, and Mounjaro—are being investigated for their protective effects against certain cancers.
A landmark study conducted at the University of California San Diego (UCSD) and published in Cancer Investigation in November 2025 has revealed a significant correlation between GLP-1 therapy and reduced mortality in colon cancer patients reported November 14, 2025. The research, led by Raphael Cuomo, an associate professor in the Department of Anesthesiology and member of the Moores Cancer Center, analyzed the medical records of more than 6,800 patients with colon carcinoma.
The findings were striking: only 15.5% of patients receiving GLP-1 therapy died within five years, compared to 37.1% of those who were not taking the medication. This suggests that GLP-1 agonists may do more than just manage weight; they may have a direct protective effect on the tumor microenvironment, potentially slowing the progression of the disease or increasing the patient’s resilience to the cancer.
Key Findings: GLP-1 Agonists and Colon Cancer
| Patient Group | 5-Year Mortality Rate |
|---|---|
| Patients on GLP-1 Therapy (e.g., Ozempic, Wegovy) | 15.5% |
| Patients NOT on GLP-1 Therapy | 37.1% |
What Which means for the Future of Oncology
The convergence of these three paths—targeted research into metabolic reprogramming, the clinical integration of nutrition, and the use of metabolic pharmacology—signals a shift toward a more holistic, biological approach to cancer care. Instead of treating the tumor as an isolated mass, physicians are beginning to treat the entire metabolic ecosystem of the patient.
For patients, this means that the future of cancer care will likely involve highly personalized metabolic profiles. A patient’s diet and metabolic medication may be prescribed with the same precision as their chemotherapy or immunotherapy, specifically tailored to “starve” their particular type of tumor while empowering their immune system.
The success of the Ifom and Algebris Ets program over the next two years will be a critical indicator of whether these laboratory insights can be successfully converted into standardized clinical protocols. As we move closer to completing the “last mile” of this research, the goal is clear: to turn the tumor’s own growth requirements into its greatest weakness.
Medical professionals and patients interested in the latest developments in immuno-metabolism are encouraged to follow updates from the Moores Cancer Center and the Istituto Airc di Oncologia molecolare (Ifom) as new trial data becomes available.
Do you believe metabolic health should be a standard part of every oncology treatment plan? Share your thoughts in the comments below or share this article with your network to join the conversation on medical innovation.